In particular, ABCG2, also known as breast cancer resistance protein (BCRP; Mao and Unadkat, 2015), has been suggested to be closely associated with the resistance against topoisomerase I inhibitors in NSCLC, including TPT, irinotecan, and SN-38 (d’Amato et al., 2007; Fan et al., 2019). Here, ABCG2 is linked to non-small cell lung carcinoma.